Advertisement


Julie R. Park, MD, on Neuroblastoma: Results of a Children’s Oncology Group Study

2016 ASCO Annual Meeting

Advertisement

Julie R. Park, MD, of Seattle Children’s Hospital, discusses findings from this phase III trial of tandem myeloablative autologous stem cell transplant using peripheral blood stem cell as consolidation therapy for high-risk neuroblastoma (Abstract LBA3).



Related Videos

Daniel F. Hayes, MD, ASCO President 2016–2017, on His Goals for the Coming Year

Newly elected ASCO President Daniel F. Hayes, MD, of the University of Michigan Health System Comprehensive Cancer Center, talks about his vision for the society during his tenure.

Multiple Myeloma

Antonio Palumbo, MD, on Multiple Myeloma: Results From the CASTOR Trial

Antonio Palumbo, MD, of the University of Torino, discusses this phase III study of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (Abstract LBA4).

Multiple Myeloma

Antonio Palumbo, MD, on Multiple Myeloma: Results From the CASTOR Trial (Italian Language Version)

Antonio Palumbo, MD, of the University of Torino, discusses in Italian this phase III study of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (Abstract LBA4). 

 To see the English language version of this video, please click here.

Issues in Oncology

Maria Clemence Schwaederle, PharmD, on Precision Medicine: Its Impact in Refractory Malignancies

Maria Clemence Schwaederle, PharmD, of the University of California, San Diego, discusses an analysis of 13,203 patients in phase I clinical trials, which showed that a personalized strategy led to improved response rate and progression-free survival (Abstract 11520).

Lung Cancer

Luis G. Paz-Ares, MD, PhD, on NSCLC: Results From the SQUIRE Trial

Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 De Octubre, discusses study findings on adding necitumumab to gemcitabine and cisplatin chemotherapy in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.

To see Dr. Paz-Ares discuss this video in Spanish, please click here.

Advertisement

Advertisement




Advertisement